PD1 TurboCAR T cell therapy - Allogene Therapeutics
Alternative Names: PD1 Turbo chimeric antigen receptors T cell therapy; PD1 TurboCAR™ T cells; PD1-TurboCAR-T-cell therapyLatest Information Update: 18 Jan 2022
At a glance
- Originator Allogene Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Jan 2022 Allogene therapeutics in-licenses miRNA technology (miCAR™) from Antion Biosciences
- 10 Apr 2021 Preclinical trials in Cancer in USA (Parenteral)
- 10 Apr 2021 Pharmacodynamics data from a preclinical trial in solid tumours presented at the American Association for Cancer Research Annual Meeting (AACR-2021)